Rationale for purging in autologous stem cell transplantation.
The success of autologous stem cell transplantation using bone marrow or peripheral blood stem cells depends not only on in vivo irradication of the disease by cytotoxic therapy but also on complete hematopoietic engraftment with no risk of relapse from the infused cells. Various methods are available for removing (purging) such contaminants. Purging techniques were developed by use of various in vitro models utilizing cell lines and fresh cancer cells. Once effective conditions were developed, they were advanced onto clinical trials. Various approaches for purging have been used. Subgroups of leukemia and lymphoma have now shown clinical benefit by the use of purged stem cells. Emphasis is now being placed on utilizing the information already obtained by the pre-clinical investigators on designing better clinical trials.
Gulati
S C
SC
Cornell Medical Center, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Acaba
L
L
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D001804:Blood Transfusion, Autologous; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000628:therapy; D016465:Bone Marrow Purging; D002460:Cell Line; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007937:Leukapheresis / Q000379:methods; D007938:Leukemia / Q000188:drug therapy / Q000628:therapy; D008223:Lymphoma / Q000188:drug therapy / Q000628:therapy; D009363:Neoplasm Proteins / Q000097:blood; D011518:Proto-Oncogene Proteins / Q000097:blood; D019253:Proto-Oncogene Proteins c-bcl-2; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2